{
    "clinical_study": {
        "@rank": "110999", 
        "arm_group": [
            {
                "arm_group_label": "MEDI7183 dose 1", 
                "arm_group_type": "Experimental", 
                "description": "Double blinded"
            }, 
            {
                "arm_group_label": "MEDI7183 dose 2", 
                "arm_group_type": "Experimental", 
                "description": "Double blinded"
            }, 
            {
                "arm_group_label": "MEDI7183 dose 3", 
                "arm_group_type": "Experimental", 
                "description": "Double blinded"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Double blinded"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multi-centre, randomised, double-blind, placebo controlled, parallel group, Phase\n      II study to evaluate efficacy and safety of 3 doses of MEDI7183, in Japanese subjects with\n      moderate to severe UC"
        }, 
        "brief_title": "MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Ulcerative Colitis", 
        "condition_browse": {
            "mesh_term": [
                "Colitis", 
                "Colitis, Ulcerative", 
                "Ulcer"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provision of informed consent prior to any study specific procedures\n\n          -  Diagnosis of UC established by clinical and endoscopic evidence and corroborated by a\n             histopathology report\n\n          -  Moderate to severe active UC as defined by a total Mayo score of 6 to 12 with\n             rectosigmoidoscopy score \u2265 2 during screening period\n\n          -  Demonstrated an inadequate response to, loss of response to, or intolerance to at\n             least one of immunomodulators or Anti- TNF-\u03b1 agents.   etc.\n\n        Exclusion Criteria:\n\n          -  Disease limited to the rectum\n\n          -  Toxic megacolon\n\n          -  Crohn's Disease\n\n          -  History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch,\n             Koch pouch, or ileostomy for UC\n\n          -  Planned bowel surgery within 12 weeks from Visit 2\n\n          -  Stool positive for C. difficile toxin at screening\n\n          -  Primary Sclerosing Cholangitis\n\n          -  History of gastrointestinal surgery within 8 weeks of Visit 2\n\n          -  Any uncontrolled or clinically significant systemic disease\n\n          -  Condition or disease that, in the opinion of the investigator would pose a risk to\n             subject safety or interfere with study evaluation, procedures or completion\n\n          -  Subjects with positive HBsAg, HBsAb, HBcAb or HCVAb serology at screening etc"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959165", 
            "org_study_id": "D5172C00001"
        }, 
        "intervention": [
            {
                "arm_group_label": "MEDI7183 dose 1", 
                "description": "MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8", 
                "intervention_name": "MEDI7183 low dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MEDI7183 dose 2", 
                "description": "MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8", 
                "intervention_name": "MEDI7183 medium dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MEDI7183 dose 3", 
                "description": "MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8", 
                "intervention_name": "MEDI7183 high dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo will be administered by SC on Day 1, Week 2,4, and 8", 
                "intervention_name": "Matching Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Ulcerative Colitis, Japanese, subcutaneously", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chikushino-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fujiidera-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuyama-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fushimi-ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamamatsu-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kagoshima-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kamakura-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyoto-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Meguro-Ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minato-ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagoya-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Niigata-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nishinomiya-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sakura-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sayama-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Takatsuki-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokkaichi-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yokohama-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "other_outcome": [
            {
                "description": "Total Mayo Score and Partial Mayo Score at each assessment, and individual Mayo sub-score (ie, stool frequency, rectal bleeding, rectosigmoidoscopy, physician's global assessment) at each assessment", 
                "measure": "Mayo score", 
                "safety_issue": "No", 
                "time_frame": "0-76 weeks"
            }, 
            {
                "description": "Change in CRP at selected time points", 
                "measure": "C-Reactive Protein", 
                "safety_issue": "No", 
                "time_frame": "0-76 weeks"
            }, 
            {
                "description": "Exposure-response relationship for efficacy as measured by the total Mayo and Partial Mayo Score", 
                "measure": "PK/PD", 
                "safety_issue": "No", 
                "time_frame": "0-76 week"
            }, 
            {
                "description": "Patient perception of change in disease, as measured by Patient Global Rating of Change", 
                "measure": "Patient perception of change in disease", 
                "safety_issue": "No", 
                "time_frame": "0-12 week"
            }, 
            {
                "description": "Inflammatory Bowel Disease Questionnaire total score and subscores from the 4 sub-domains: Bowel symptoms, systemic symptoms, emotional function, and social function", 
                "measure": "IBDQ", 
                "safety_issue": "No", 
                "time_frame": "0-12 week"
            }, 
            {
                "description": "Bowel movements, symptom severity and coping activities as measured by the Ulcerative Colitis Patient Reported Outcome (UC PRO) modules 1-3.", 
                "measure": "UCPRO module 1 - 3", 
                "safety_issue": "No", 
                "time_frame": "0-12 week"
            }, 
            {
                "description": "Emotional impact and impact on daily life as measured by the UC PRO modules 4 and 5", 
                "measure": "UCPRO module 4 & 5", 
                "safety_issue": "No", 
                "time_frame": "0-12 week"
            }
        ], 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Kanetoshi Washio", 
            "phone": "+81 6 6453 7356"
        }, 
        "overall_contact_backup": {
            "email": "Masataka.Date@astastrazeneca.com", 
            "last_name": "Masataka Date, MD", 
            "phone": "+81 6 6453 8023"
        }, 
        "overall_official": [
            {
                "affiliation": "Centre for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University", 
                "last_name": "Toshifumi Hibi, Director and Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AztraZeneca, Osaka, Japan", 
                "last_name": "Masataka Date, Study Physician", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Remission rate defined as a total Mayo Score \u2264 2 points, and with no individual subscore > 1 point.", 
            "measure": "Remission rate", 
            "safety_issue": "No", 
            "time_frame": "Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959165"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Response rate assessed by total Mayo score.  Response is defined as decrease \u2265 3 points and 30% in total Mayo Score compared to baseline (Visit 1), and with an accompanying decrease in the subscore for rectal bleeding of \u22651 point or with an absolute subscore for rectal bleeding of 0 or 1", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }, 
            {
                "description": "Mucosal healing rate at Week 8 defined as an absolute Mayo subscore for rectosigmoidoscopy of 0 or 1", 
                "measure": "Mucosal healing rate", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }, 
            {
                "description": "Response at Week 12 assessed by PMS. Response is defined as reduction by \u22652 points and 25% in PMS compared to baseline (Visit 1)", 
                "measure": "Response rate assessed by PMS", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }, 
            {
                "description": "Adverse events, serious adverse events, discontinuations of investigational product due to adverse events (DAEs), laboratory values and vital signs through 28 weeks after last dose of MEDI7183", 
                "measure": "Safety and torelability assessed by adverse event rate etc", 
                "safety_issue": "Yes", 
                "time_frame": "0-76 weeks"
            }, 
            {
                "measure": "Pharmacokinetics assessed by Serum concentration", 
                "safety_issue": "No", 
                "time_frame": "0-76 weeks"
            }, 
            {
                "description": "Receptor Occupancy and memory CD4 \u03b14\u03b27 hi (CD4 circulating lymphocytes expressing high levels of \u03b14\u03b27-integrin) cell numbers over time", 
                "measure": "Pharmacodynamics assessed by Receptor Occupancy and memory CD4 \u03b14\u03b27 hi cell numbers", 
                "safety_issue": "No", 
                "time_frame": "0-12 weeks"
            }, 
            {
                "description": "Anti- MEDI7183 antibodies", 
                "measure": "Anti- MEDI7183 antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "0-76 weeks"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}